Membrane microdomains and vascular biology: Emerging role in atherogenesis

Circulation

Volumn 107, Issue 17, 2003, Pages 2270-2273

  Mason, R Preston ^a,b,c   Jacob, Robert F ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b ELUCIDA RESEARCH LLC   (United States)

^c 100 Cummings Center ^*  (United States)

Author keywords

Atherosclerosis; Cholesterol; Lipids; Pharmacology; Vasculature

Indexed keywords

ATORVASTATIN; CALCIUM; CALMODULIN; CHOLESTEROL; GUANINE NUCLEOTIDE BINDING PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; NITRIC OXIDE SYNTHASE; SPHINGOLIPID;

ATHEROGENESIS; CELL MEMBRANE; CELL TYPE; ENDOTHELIUM CELL; EXERCISE TOLERANCE; GENETIC ENGINEERING; HUMAN; LIPID BILAYER; MEMBRANE BINDING; MEMBRANE BIOLOGY; MICROSCOPIC ANATOMY; MUSCLE CELL; PRIORITY JOURNAL; PROTEIN DOMAIN; REVIEW;

ANIMALS; ARTERIOSCLEROSIS; BLOOD VESSELS; CHOLESTEROL; CRYSTALLIZATION; ENDOTHELIUM, VASCULAR; HUMANS; MEMBRANE MICRODOMAINS; MODELS, CARDIOVASCULAR; MUSCLE, SMOOTH, VASCULAR; RECEPTORS, DRUG;

EID: 0038034482     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000062607.02451.B6     Document Type: Review

References (22)

1. Brown DA, London E. Structure and function of sphingolipid- and cholesterol-rich membrane rafts. J Biol Chem. 2000;275:17221-17224.
2. Smart EJ, Graf GA, McNiven MA, et al. Caveolins, liquid-ordered domains, and signal transduction. Mol Cell Biol. 1999;19:7289-7304.
3. Feron O, Belhassen L, Kobzik L, et al. Endothelial nitric oxide synthase targeting to caveolae. J Biol Chem. 1996;271:22810-22814.
4. Drab M, Verkade P, Elger M, et al. Loss of caveolae, vascular dysfunction, and pulmonary defects in caveolin-1 gene-disrupted mice. Science. 2001;293:2449-2452.
5. Simons K, Ehehalt R. Cholesterol, lipid rafts, and disease. J Clin Invest. 2002;110:597-603.
6. Feron O, Dessy C, Desager JP, et al. Hydroxy-methyglutaryl-coenzyme A reductase inhibition promotes endothelial nitric oxide synthase activation through a decrease in caveolin abundance. Circulation. 2001;103: 113-118.
7. Harrison DG. Cellular and molecular mechanisms of endothelial cell dysfunction. J Clin Invest. 1997;100:2153-2157.
8. Tulenko TN, Chen M, Mason PE, et al. Physical effects of cholesterol on arterial smooth muscle membranes: evidence of immiscible cholesterol domains and alterations in bilayer width during atherogenesis. J Lipid Res. 1998;39:947-956.
9. Kellner-Weibel G, Yancey PG, Jerome WG, et al. Crystallization of free cholesterol in model macrophage foam cells. Arterioscler Thromb Vasc Biol. 1999;19:1891-1898.
10. Craven BM. Crystal structure of cholesterol monohydrate. Nature. 1976; 260:727-729.
11. Phillips JE, Geng YJ, Mason RP. 7-Ketocholesterol forms crystallin domains in model membranes and murine aortic smooth muscle cells. Atherosclerosis. 2001;159:125-135.
12. Jacob RF, Cenedella RJ, Mason RP. Direct evidence for immiscible cholesterol domains in human ocular lens fiber cell plasma membranes. J Biol Chem. 1999;274:31613-31618.
13. Vergani L, Hatrik S, Ricci F, et al. Effect of native and oxidized low-density lipoprotein on endothelial nitric oxide and superoxide production: key role of L-arginine availability. Circulation. 2000;101:1261-1266.
14. Chang HM, Reitstetter R, Mason RP, et al. Attenuation of channel kinetics and conductance by cholesterol: an interpretation using structural stress as a unifying concept. J Membr Biol. 1995;143:51-63.
15. Gleason MM, Medow MS, Tulenko TN. Excess membrane cholesterol alters calcium movements, cytosolic calcium levels, and membrane fluidity in arterial smooth muscle cells. Circ Res. 1991;69:216-227.
16. Small DM. Progression and regression of atherosclerotic lesions. Arteriosclerosis. 1988;8:103-129.
17. Libby P. Molecular bases of the acute coronary syndromes. Circulation. 1995;91:2844-2850.
18. Mason RP, Rhodes DG, Herbette LG. Reevaluating equilibrium and kinetic binding parameters for lipophilic drugs based on a structural model for drug interaction with biological membranes. J Med Chem. 1991;34:869-877.
19. Mason RP. Membrane interaction of calcium channel antagonists modulated by cholesterol: implications for drug activity. Biochem Pharmacol. 1993;45:2173-2183.
20. Mason RP. Mechanisms of plaque stabilization for the dihydropyridine calcium channel blocker amlodipine: review of the evidence. Atherosclerosis. 2002;165:191-199.
21. Pitt B, Byington RP, Furberg CD, et al. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. Circulation. 2000;102:1503-1510.
22. Borhani NO, Mercuri M, Borhani PA, et al. Final outcome results of the Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS): a randomized controlled trial. JAMA. 1996;276:785-791.